AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03783949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: In combination with Gemcitabine: Carboplatin dose will be AUC4 (q3w) In combination with Paclitaxel: Carboplatin dose will be AUC5 (q3w)
Study NCT03783949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel dose will be 175mg/m² (q3w)
Study NCT03783949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine dose will be 1000mg/m² (q3w, d1 \& d8)
Study NCT02751528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-021
Description: ETBX-021 is a HER2-targeting vaccine comprising an Ad5 vector and a modified HER2 gene insert.
Study NCT02821013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent PD-1 inhibitor therapy
Study NCT03758755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy
Description: A wide pressure cuff will be applied to the upper thigh prior to starting strengthening exercises. The cuff is inflated to 80% of resting systolic blood pressure. The cuff remains inflated for the entirety of the exercise (4 sets of a specific movement). Once the exercises are completed, it is deflated for a minimum of one minute before the next type of exercises are started.
Study NCT03758755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACL Reconstruction rehabilitation
Description: post-operative rehabilitation according to current standards of care
Study NCT02821013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous PD-1 inhibitor therapy
Study NCT04783571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Auditory stimulation will not be delivered during the nap
Study NCT04783571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory Stimulation
Description: Auditory stimulation will be delivered during the nap
Study NCT03546361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cell-Adenovirus CCL21 Vaccine
Description: Given via CT-guided or bronchoscopic IT injection
Study NCT03546361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02022605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hands-on EMS training
Description: A trainer (SAH) gave a series of demonstrations of the proper techniques of ERCP step by step on the EMS. The demonstration included selective cannulation, sphincterotomy, guidewire exchange, balloon dilation, stone extraction and stent insertion. Then trainees practiced each technique with hands-on coaching from the trainer on the EMS. Each trainee could repeate the practice with the trainer giving only verbal correction of any errors for about 30min.
Study NCT03817983 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRE review for evidence of axSpA in SIJs
Description: Screening for evidence of axSpA on the MRE scan of patients with Crohn's disease
Study NCT03817983 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical assessment and dedicated MRI of the spine and pelvis
Description: Clinical assessment and dedicated MRI of the spine and pelvis to assess for evidence of axSpA
Study NCT02022605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard training
Description: The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of CBD or PD. During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within 10min, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
Study NCT02022605 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard training
Description: The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of CBD or PD. During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within 10min, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
Study NCT02257047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Tea
Study NCT02257047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RYR
Description: red yeast rice
Study NCT00419471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Study medication will be provided as 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day, and matched placebo. The initial dose of escitalopram was 10mg/day generally, but 5mg/day for those aged 65 or over and with hepatic dysfunction. After the 2nd evaluation, the treatment doses are determined by the investigators' clinical decision considering the severity of depression and tolerability of drug. Drugs are taken once daily per orally within 30 min after the supper meal.
Study NCT00419471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo medication will be provided as matched 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day.
Study NCT04206878 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-care birth test
Description: Collect quantitative data through clinical chart and form abstractions; collect qualitative data through in-depth interviews with caregivers, health workers and policymakers
Study NCT03399266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double Balloon catheter for induction of labor
Description: With the patient in lithotomy position or lying supine in bed, a speculum is inserted to visualise the cervix. The device is inserted into the cervix using long forceps until both balloons enter the cervical canal. Then, the uterine balloon is inflated with 20 ml of saline (by means of a 20 ml syringe). The device is then pulled out until stopped by the uterine balloon covering the internal cervical os. At this point the cervico-vaginal balloon located at the external os is inflated with 20 ml of saline and the speculum is removed. Then both balloons are additionally inflated with alternate increments of 20 ml normal saline to a total volume of 80 ml in each balloon. The device is loosely taped to the patient's inner thigh.
Study NCT03690310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR NK Cells
Description: Anti-CD19 CAR NK Cells injection
Study NCT00364689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Study NCT00364689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Study NCT00364689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Study NCT00364689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT06536452 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT01748604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lymphatic Drainage (MLD)
Description: MLD with Földi's technique by an expert therapist during 45 minutes
Study NCT01748604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic intermittent pneumatic compression Device (IPC)
Description: Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes.
Study NCT01748604 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Generic intermittent pneumatic compression Device (IPC)
Description: Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes.
Study NCT01748604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multilayer, multicomponent bandages (MB)
Description: multilayer, multicomponent bandages (MB) until next day.
Study NCT01748604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multilayer, multicomponent bandages (MB)
Description: multilayer, multicomponent bandages (MB) until next day.
Study NCT01748604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lymphapress-Plus(TM) device (LPD)
Description: Pneumatic massage with Lymphapress-Plus(TM)device that was lent during the duration of the study during 20 minutes.
Study NCT04755517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frequent information of cytological/ HPV DNA screening results
Description: All participants will be referred to pertinent diagnosis and treatment according to local standard of care (Käypä hoito 2010) should the cytological screening results (HSIL, ASC-H, AGC-FN) or three consecutive LSIL findings at repeated control visits within 3 years indicate it. The most common screening results (ASCUS, LSIL) are, however, not convened to arm A2 participants before age 28.~All cytology and HPV DNA results results are being revealed to all trial participants at age 28 at the study end.
Study NCT03758755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction rehabilitation
Description: post-operative rehabilitation according to current standards of care
Study NCT04458051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Pharmaceutical form: Film-coated Tablet Route of administration: Oral
Study NCT04458051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Film-coated Tablet Route of administration: Oral
Study NCT03621670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)
Description: Bexsero is to be administered intramuscularly on upper side of the right thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group.
Study NCT03621670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar13
Description: Prevnar13 (PCV13) is to be administered intramuscularly on upper side of the left thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
Study NCT03621670 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Prevnar13
Description: Prevnar13 (PCV13) is to be administered intramuscularly on upper side of the left thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
Study NCT03621670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix
Description: Pediarix (DTPa-HBV-IPV) is to be administered intramuscularly on lower side of the left thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
Study NCT03621670 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pediarix
Description: Pediarix (DTPa-HBV-IPV) is to be administered intramuscularly on lower side of the left thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
Study NCT03621670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix
Description: Hiberix (Hib) is to be administered intramuscularly on lower side of the right thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
Study NCT03621670 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hiberix
Description: Hiberix (Hib) is to be administered intramuscularly on lower side of the right thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
Study NCT03621670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Rotarix (HRV) is to be administered orally as a 2-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) to all subjects in the MenB+PCV group and Placebo+PCV group.
Study NCT03621670 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rotarix
Description: Rotarix (HRV) is to be administered orally as a 2-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) to all subjects in the MenB+PCV group and Placebo+PCV group.
Study NCT03621670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R II
Description: M-M-R II (MMR) is to be administered subcutaneously on upper side of the right arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
Study NCT03621670 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: M-M-R II
Description: M-M-R II (MMR) is to be administered subcutaneously on upper side of the right arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
Study NCT03621670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax
Description: Varivax (VV) is to be administered subcutaneously on upper side of the left arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
Study NCT03621670 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Varivax
Description: Varivax (VV) is to be administered subcutaneously on upper side of the left arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
Study NCT03621670 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline water)
Description: Placebo is to be administered intramuscularly on upper side of the right thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the Placebo+PCV group.
Study NCT03621670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 20
Description: Prevnar 20 (PCV13) is to be administered intramuscularly as a booster dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose.
Study NCT03621670 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Prevnar 20
Description: Prevnar 20 (PCV13) is to be administered intramuscularly as a booster dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose.
Study NCT02630901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX003
Study NCT02630901 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01590173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone and Heparin during COH for IVF
Description: Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day and 5 mg prednisolone p.os (Prezolon; Nycomed Hellas SA) were to be initiated on the first day of injections in both protocols until the pregnancy test. In cases of pregnancy, prednisolone and enoxaparin were to be continued up to the 12th and 34th week, respectively
Study NCT03513341 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention is given to the participants. This is an observational study exploring the students' levels of physical activity and sedentary behaviour in their natural setting.
Study NCT04253886 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ovassapian Fibreoptic Intubating Airway
Description: The fibreoptic bronchoscope remains one of the most important methods of intubating patients particularly when there is difficulty with intubation.Facilitating fiberoptic oropharyngeal intubation procedure, specific airways have been devised to push the tongue anteriorly to clear a passage for the fibrescope into the trachea. Of these airways Ovassapian Fibreoptic Intubating Airway (Kendall, Argyle, New York, New York, USA) and Fekry Oral Intubating Airway (Ameco Tech, Cairo, Egypt).
Study NCT01267357 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT03893695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT90001 and Nivolumab
Description: Stage1:Dose de-escalation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
Study NCT02193906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients who have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb® during 3 months. Patients who don't have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb Monthly Notebooks® during 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
Study NCT02193906 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo task
Description: Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients will have to complete a placebo task (send an email with a copy of a journal/magazine heading) a minimum of 3 times a week, for 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
Study NCT03217253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03217253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03217253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO
Study NCT01590173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COH for IVF
Description: Both GnRH agonists (long, starting at day 2 or 21) with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany) and antagonists' with ganirelix 0.25 mg (Orgalutran; Organon, Oss, The Netherlands) or cetrorelix 0.25 mg (Cetrotide; Serono, Rome, Italy) protocols will be used; for ovarian stimulation both recombinant FSH (Puregon; Organon, Oss, Netherlands or Gonal F; Serono, Rome, Italy) and human menopausal gonadotrophin (Menopur; Ferring Pharmaceuticals, Langley, Berkshire, UK) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the hCG triggering and for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied.
Study NCT02583685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR4 + LDV/SOF + ASV 4 wk
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
Study NCT02583685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR4 + LDV/SOF + SMV 4 wk
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Study NCT02583685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR4 + LDV/SOF + ASV 6 wk
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
Study NCT02583685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR4 + LDV/SOF + SMV 6 wk
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Study NCT02583685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR4 + LDV/SOF + ASV 8 wk
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.